PDS Biotechnology Corporation
NASDAQ:PDSB · NASDAQ Capital Market
+$0.01 today
Vol 0.42M · Avg 1.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-372.9%
avg -114.0%
ROIC
-116.5%
avg -64.6%
ROA
-113.1%
avg -60.6%
Analysis
ROA is currently the strongest return metric at -113.1% versus its period average of -60.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Frank K. Bedu-Addo | President, Chief Executive Officer & Director | $634,807.00 | — | 60 | $548,782.00 | 0.98% |
Kirk V. Shepard | Chief Medical Officer | $483,818.00 | — | 74 | $300,000.00 | 0.54% |
Stephan Toutain | Chief Operating Officer | $480,129.00 | — | 60 | $300,000.00 | 0.54% |
Gregory L. Conn | Chief Scientific Officer | $194,672.00 | — | 70 | $150,000.00 | 0.27% |
Lars Robert Boesgaard | Principal Financial & Accounting Officer and Chief Financial Officer | — | — | 56 | $300,000.00 | 0.54% |
Janetta Trochimiuk | Controller | — | — | 63 | $0.00 | <0.01% |
Spencer Brown | Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | — | — | 56 | $300,000.00 | 0.54% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Xilio Therapeutics, Inc.
NASDAQ:XLO
$61.12M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$58.45M
Kezar Life Sciences, Inc.
KZR
$53.86M
LAVA Therapeutics N.V.
LVTX
$45.77M
FibroGen, Inc.
FGEN
$36.69M
INmune Bio, Inc.
INMB
$36.55M
Annovis Bio, Inc.
ANVS
$34.92M
Actinium Pharmaceuticals, Inc.
ATNM
$32.21M
Tempest Therapeutics, Inc.
TPST
$5.49M
Reviva Pharmaceuticals Holdings, Inc.
RVPH
$2.05M
Who manages PDSB?
PDS Biotechnology Corporation (PDSB) lists 7 active executives. The top listed executive is Gregory L. Conn, Chief Scientific Officer.
Are PDSB insiders buying or selling?
Recent insider activity shows net buying of $13.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.